U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C18H27NO2
Molecular Weight 289.4125
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of CARAMIPHEN

SMILES

CCN(CC)CCOC(=O)C1(CCCC1)C2=CC=CC=C2

InChI

InChIKey=OFAIGZWCDGNZGT-UHFFFAOYSA-N
InChI=1S/C18H27NO2/c1-3-19(4-2)14-15-21-17(20)18(12-8-9-13-18)16-10-6-5-7-11-16/h5-7,10-11H,3-4,8-9,12-15H2,1-2H3

HIDE SMILES / InChI

Molecular Formula C18H27NO2
Molecular Weight 289.4125
Charge 0
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description

Caramiphen is a muscarinic M1 acetylcholine receptor antagonist, which was used for the treatment of Parkinson Disease and cough, but then there using were discontinued. Caramiphen is also used in local anesthesia, and effect could be achieved through the suppression of voltage-gated Na⁺ currents.

Approval Year

Targets

Primary TargetPharmacologyConditionPotency
52.1 µM [IC50]
1.2 nM [Ki]

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
SKF TUSS-ORNADE
Primary
parpanit

Doses

AEs

PubMed

Sample Use Guides

In Vivo Use Guide
2.5 to 6.0 mg/kg
Route of Administration: Intravenous
In Vitro Use Guide
It was investigated the effect of caramiphen (300uM) on voltage-gated sodium channels in differentiated neuronal NG108-15 cells. Caramiphen exhibited a milder state-dependence of block (IC₅₀ of 52.1 and 99.5 µM at holding potentials of -70 and -100 mV, respectively).
Substance Class Chemical
Record UNII
97J7NP0XJY
Record Status Validated (UNII)
Record Version